Antipsychotic News and Research

RSS

Antipsychotics are medicines used to treat the symptoms of mental disorders such as schizophrenia, depression, bipolar disorder (sometimes called manic-depressive illness), anxiety disorders, and attention deficit-hyperactivity disorder (ADHD). Sometimes medications are used with other treatments such as psychotherapy.

MGH Bipolar CHOICE trial to evaluate effectiveness of new medications compared to lithium

The Massachusetts General Hospital (MGH) Bipolar Clinic and Research Program with the Bipolar Trials Network is launching Bipolar CHOICE, a 10-site nationwide trial evaluating the real-world advantages and disadvantages of quetiapine, a widely prescribed second generation antipsychotic mood stabilizing medication, compared to lithium, the gold standard mood stabilizer, for the treatment of outpatients with bipolar disorder.

21 Jan 2011

Positive top-line results from TC-5619 Phase 2 trial in patients with schizophrenia

Targacept, Inc. today announced positive top-line results from a Phase 2 clinical proof of concept trial to assess TC-5619 as an augmentation therapy to improve cognition in patients with schizophrenia.

20 Jan 2011

UH, Case Western University commence clinical trial for bipolar disorder

The Mood Disorders Program at Case Western Reserve University School of Medicine and University Hospitals Case Medical Center, along with the Bipolar Trials Network, is launching Bipolar CHOICE.

12 Jan 2011

CAMH scientists receive NARSAD's Young Investigator grant awards for brain and behavior research

Seven scientists at Canada's Centre for Addiction and Mental Health have been awarded Young Investigator grant awards by the U.S.-based NARSAD: The Brain and Behavior Research Fund.

12 Jan 2011

Stigma remains over Major Depressive Disorder

Despite there being 39.1 million people suffering from major depressive disorder (MDD) across the seven major markets, only one third of patients will seek help from a physician, finds latest research from independent analyst Datamonitor.

11 Jan 2011

Mithridion secures commitments of $1.25 million in new funding

Mithridion, Inc., a privately-owned clinical stage drug development company focusing on serious Central Nervous System disorders, including Alzheimer's disease, announces that it has secured commitments of $1.25 million in new funding.

11 Jan 2011

Whites with mutations more likely to be susceptible to cocaine abuse

Nearly one in five whites could carry a genetic variant that substantially increases their odds of being susceptible to severe cocaine abuse, according to new research.

21 Dec 2010

Sunovion reports results of Latuda third phase 3 worldwide clinical trial for schizophrenia

Sunovion Pharmaceuticals Inc. today announced the results of the PEARL 3 study, the third phase 3 worldwide clinical trial of Latuda® (lurasidone HCl) tablets, a once-daily atypical antipsychotic agent recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with schizophrenia. In this six-week, placebo-controlled trial, both fixed doses of LATUDA 80 and 160 mg once-daily, demonstrated statistically significant improvement in symptoms of schizophrenia versus placebo across both primary and secondary efficacy measures.

9 Dec 2010

Cyrenaic announces results of CYR-101 Phase IIa clinical trial for schizophrenia

Cyrenaic Pharmaceuticals Inc. a private drug development company focused on the treatment of CNS disorders, today announced Phase IIa clinical results for CYR-101, its novel investigational drug for the treatment of schizophrenia. The results from the study showed that the drug alleviated the symptoms of the disease, including the negative and cognitive symptoms.

30 Nov 2010

Psychiatric hospitalization rate decreases among adults with schizophrenia treated with INVEGA SUSTENNA: Study

Schizophrenia is a chronic and disabling brain disorder that affects 1 percent of the U.S. population and results in substantial medical and societal costs, in particular from use of health-care resources. It also can have devastating health-related and social effects on people with the disease, their families and caregivers.

20 Nov 2010

Mass. regulators and nursing homes fight inappropriate medicating; officials deal with Hawaii doctor shortage

State regulators and the Massachusetts nursing home industry are launching a campaign today to reduce the inappropriate use of antipsychotic medications for residents with dementia.

19 Nov 2010

Alkermes's ALKS 33 drug candidate offers potential treatment for multiple disease indications

Alkermes, Inc. today announced the presentation of promising preclinical results for its proprietary opioid modulator, ALKS 33, showing the drug candidate's potential in multiple disease indications.

17 Nov 2010

No difference in risk of nonsuicide death between ziprasidone and olanzapine for schizophrenia

The potential for harmful side effects associated with anti-psychotic medications for treating schizophrenia is a frustration for mental-health professionals who must balance this with the positive benefits of drugs. For example, the issue of the antipsychotic drug ziprasidone lengthening the QTc interval, a possible indicator of life-threatening heart arrhythmias, has demanded much attention among clinicians since the drug was introduced in 2001.

15 Nov 2010

Latuda tablets receive FDA approval for treatment of adults with schizophrenia

The U.S. Food and Drug Administration today approved Latuda (lurasidone HCl) tablets for the treatment of adults with schizophrenia.

29 Oct 2010

Quebec recognizes value of ABILIFY for treating schizophrenia and related psychotic disorders

Bristol-Myers Squibb Canada is pleased to announce that Quebec has recognized the value of ABILIFY (aripiprazole) for the treatment of schizophrenia and related psychotic disorders in adults and has agreed to list ABILIFY as a reimbursed full benefit on the Quebec public drug plans as of October 14, 2010.

27 Oct 2010

Pledge to reduce antipsychotic use in dementia sufferers

A new coalition of 44 organizations called the Dementia Action Alliance, has called for a cut in the use of anti-psychotic drugs for patients with dementia. The coalition includes Alzheimer's Research Trust, Alzheimer's Society, BUPA, Dementia UK, the Royal College of Psychiatrists, Royal College of General Practitioners and Stroke Association.

26 Oct 2010

Johnson & Johnson third quarter sales decrease 0.7% to $15.0 billion

Johnson & Johnson today announced sales of $15.0 billion for the third quarter of 2010, a decrease of 0.7% as compared to the third quarter of 2009. Operational results increased 0.1% and the negative impact of currency was 0.8%. Domestic sales declined 2.5%, while international sales increased 1.1%, reflecting operational growth of 2.6% and a negative currency impact of 1.5%.

19 Oct 2010

Lannett announces launch of Fluphenazine HCl Tablets

Lannett Company, Inc., a manufacturer of generic pharmaceuticals, today announced that it has commenced shipping Fluphenazine HCl Tablets USP, the generic equivalent of Prolixin®, in 1 mg, 2.5 mg, 5 mg and 10 mg dosages. For the 12 months ended September 2010, Fluphenazine HCl Tablets USP, 1 mg, 2.5 mg, 5 mg, & 10 mg had U.S. sales of approximately $28 million at Average Wholesale Price.

18 Oct 2010

Lundbeck, Merck announce commercialization agreement for SYCREST sublingual tablets

H. Lundbeck A/S (Lundbeck) and Merck, known outside the United States and Canada as MSD, today announced a commercialization agreement for SYCREST (asenapine) sublingual tablets (5 mg, 10 mg). Under the terms of the agreement, Lundbeck will pay an undisclosed fee as well as product supply payments in exchange for exclusive commercial rights to SYCREST in all markets outside the United States, China and Japan. Lundbeck expects to launch SYCREST in the European Union (EU), where it is already approved, at the beginning of 2011.

12 Oct 2010

IDMC recommends early termination of Phase 3 intramuscular depot aripiprazole trial

Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) announced today that an independent data monitoring committee (IDMC) has recommended the early termination of its Phase 3, 52-week, placebo-controlled, intramuscular depot aripiprazole trial.

6 Oct 2010